Introduction
The Marfan syndrome is a systemic disorder of connective tissue with autosomal dominant inheritance and an estimated prevalence of at least 5-10 per 100,000 population. Approximately one-quarter of patients are born to parents who are not clinically affected, and are thought to result from parental germinal mutations (1) . Cardinal manifestations involve the eye Receivedfor publication 18 November 1991 and in revisedform 18 December 1991. (lens dislocation, myopia), skeleton (dolichostenomelia, arachnodactyly, anterior chest deformity, spinal curvature, joint laxity), and cardiovascular system (aortic root dilatation and dissection, mitral valve prolapse, mitral and aortic valve regurgitation) (2) . Other clinical signs include retinal detachment, dysrhythmia, pneumothorax, striae distensae, inguinal hernia and dural ectasia (1, 3, 4) . The Marfan syndrome shows high penetrance but interfamilial and, to a lesser extent, intrafamilial clinical variability is the rule (3) .
The gene and protein defective in the Marfan syndrome have only recently been identified. In 1986, Sakai et al. (5) first identified fibrillin, a 350-kD glycoprotein component of the extracellular microfibril, and demonstrated that this protein is an abundant component of the tissues altered in the Marfan phenotype, namely the skin, aorta, cartilage, suspensory ligament of the ocular lens, and the alveolar wall. Subsequent immunohistopathologic study ofMarfan patient tissues, using fluorescent monoclonal antibodies to fibrillin (6) , and examination of fibrillin synthesis, extracellular transport and incorporation into the extracellular matrix (7) showed abnormalities of fibrillin metabolism in the majority of patients.
Recently, linkage of the Marfan locus to anonymous DNA markers on chromosome 1 5q in families from diverse ethnic backgrounds was reported (8, 9) . A portion of the cDNA encoding fibrillin was cloned and sequenced (10) . Polymorphisms detected by fibrillin cDNA were used to demonstrate tight linkage between the fibrillin locus and both the Marfan syndrome phenotype (11, 12) and previously linked anonymous loci (1 1). This localization was consistent with the assignment of the fibrillin gene to 1 5q21.1 by in situ hybridization methods (13) . Subsequent analysis of fibrillin cDNA from patients with sporadic disease allowed the identification ofa recurrent de novo missense mutation in the fibrillin gene as the cause ofdisease in two individuals, both ofwhom had infantile presentation and severe involvement of the ocular, skeletal, and cardiovascular systems (1 1) . This mutation involved the substitution ofproline for arginine at codon 239 (10) within the repetitive epidermal growth factor (EGF)'-like motif of the fibrillin gene (R239P). In the absence of any linkage evidence for genetic heterogeneity in the Marfan syndrome, it appeared that defects in the fibrillin gene were the predominant cause of this disorder.
1. Abbreviations used in this paper: EGF, epidermal growth factor; PCR, polymerase chain reaction.
We have now identified a missense mutation in the fibrillin gene which segregates with the disease phenotype in a multiplex family. This single amino acid alteration involves the substitution of serine for cysteine at codon 1409 (C 1409S) and like R239P, occurs within the repetitive EGF-like motif. The identification of this mutation validates the prior evidence that fibrillin gene defects are centrally involved in the pathogenesis of familial Marfan syndrome.
Methods

Subjects
With the exception of extended family members of the proband, patient B.V., study participants were evaluated at the Medical Genetics Clinic ofThe Johns Hopkins Hospital. All individuals assigned affected status for the Marfan syndrome satisfied the diagnostic criteria established by Beighton et al. (14) . Data obtained included family history, physical examination, and results of echocardiography and slit-lamp examination. Phenotype data for B.V.'s family were collected from a variety of sources including family members, local practitioners, medical records, and death certificates. All living family members of the proband were examined by an internist or pediatrician, a cardiologist, and an ophthalmologist. Normal control subjects were unrelated and lacked any features of the Marfan syndrome.
Mutation identification
Single-strand conformation polymorphism analysis. Polymerase chain reaction (PCR [15] ) primers were fashioned from the published fibrillin complementary DNA (cDNA) sequence (10) . 17 primer pairs, spaced at -500 base-pair (bp) intervals with 150-bp overlap at the 5' and 3' ends, were necessary to span this portion of the fibrillin coding region. cDNA, reverse transcribed from fibroblast total RNA as described (11) , from 26 unrelated patients with the Marfan syndrome and two control subjects was screened for point mutations. C1409S was detected using primers F12S (5'-ATGGAACCTGCAAGAATGTG-3') and F12AS (5'-CACATGTTTTGTAGCACCTC-3'). PCR conditions for this and all subsequent reactions were denaturing at 940C for 30 s, annealing at 560C for 30 s, extension at 720C for I min (total of30 cycles), then final extension at 72°C for 10 min. Sample processing and single-strand conformation polymorphism analysis were performed as previously described (11 (16), and direct sequencing of double-stranded PCR-amplified DNA was performed by standard protocol (17) .
Population screening
Marfan and control populations were screened for the presence of C1409S as well as nucleotide 4194A-G and 4161C-T polymorphisms (4194A-G and 4161C-T, respectively) using PCR-amplified cDNA and/or genomic DNA. PCR amplification to screen for C 1409S used primers F13S (5'-CAGACGAAGCCAGGGATC-3') and F12AS and yielded a 158-bp fragment (cDNA) or an -800-bp fragment (genomic DNA). Amplified product using primers F12DS (5'-CCCGGGTAT-CAGCGGAG-3') and F12BAS (5'-TAGCTCCCACGGGTGTTG-3') was used to screen for 4194A-G and 416 1C-T; this reaction yielded a 100-bp fragment (cDNA) or an -2.4-kb fragment (genomic DNA). 10
,Ml of a 100-Ml PCR reaction (conditions as described above) was added to 0.5 ml of a 0.4 M NaOH, 10 mM EDTA solution and heated at 1000C for 10 min. The samples were then transferred to Zetabind transfer membrane (CUNO, Inc., Meriden, CT), prewet with distilled water, using wall vacuum and a microfiltration apparatus (Bio-Dot, Bio-Rad Laboratories, Richmond, CA). Each well was sequentially rinsed under vacuum with 0.5 ml of 0.4 M NaOH and 1.0 ml of 2x SSPE (0.3 M NaCl, 20 mM NaH2PO4, 2 mM sodium EDTA, pH 7.4).
The membrane was then air dried. Prehybridization and hybridization were performed as previously described (1 1). After hybridization the filters were washed in 2x SSPE, 0.1% SDS at room temperature for 10 min twice. The final wash was performed at 560C in 2x SSPE, 0.1% SDS for 20 min. The allele-specific oligonucleotides used to probe for each allele were as follows: C 1409 (wild type) (5'-GTTGAGG-CAGCGCCCAT-3'), S 1409 (mutant) (5'-ATGGGCGCTCCCT-CAAC-3'); T4161 (5'-CCTTCTCCATCAGGTCT-3'), C4161 (5'-AGACCTGACGGAGAAGG-3'); G4194 (5'-GGCTTCGTCTGA-CATTC-3') and A4194 (5'-GAATGTCAAACGAAGCC-3'). Filters were stripped in 0.5 N NaOH, 0.6 M NaCl at room temperature for 30 min and neutralized in 1 M Tris[hydroxymethyl]aminomethane, 0.6 M NaCl, pH 7.4 at room temperature for 30 min before rehybridization.
Results
Mutation identification. When cDNA from two control individuals and 26 unrelated probands with Marfan syndrome was PCR amplified with primers F I2S and F I2AS and subjected to single-strand conformation polymorphism analysis, an abnormally migrating band was observed in one patient (Fig. 1 A) . Direct sequencing of this region of cDNA from this individual (B.V.) revealed a G to C transversion at nucleotide 4226 (11) in one fibrillin allele (Fig. 1 B) . As shown in Fig. 1 C, the corresponding amino acid alteration is a substitution ofserine (S) for cysteine (C) at codon 1409 (C 1409S). In addition, sequence analysis showed that patient B.V. was heterozygous at nucleotides 4194 and 4161 (A-G and C-T, respectively) while the control sample was homozygous G at nucleotide 4194 and T at nucleotide 4161. These variations both represented third base substitutions (codons 1387 and 1398) without impact on amino acid sequence. Family screening. Genomic DNA was extracted from whole blood samples obtained from nine living relatives of the proband. PCR-amplified product, using primers F13S and Fl 2AS was used in dot blot analysis to screen for the presence of C 1409S. Clinical evaluation of these individuals included history, physical examination, ophthalmologic evaluation and echocardiogram. Everyone assigned affected status satisfied the established diagnostic criteria (14) , whereas those unaffected had no features of the Marfan syndrome. C 1409S was found to segregate with the disease phenotype through three generations of this family and was not observed in unaffected individuals (Fig. 2, top) . In contrast, the neutral polymorphisms A4194 and C4161 were found to be on the opposite fibrillin allele from C1409S in the proband and to segregate to unaffected individuals in the extended family. C 1409S can also be detected by restriction analysis due to the loss of both a Fnu4HI and a BbvI restriction site (data not shown).
Population screening. C1409S was not observed upon dot blot screening of 176 chromosomes from 88 unrelated individuals without manifestations of the Marfan syndrome (Fig. 2,  bottom) . In addition, testing of a proband from 60 additional families with the disease failed to demonstrate a recurrence of this mutation. Neutral polymorphisms A4194 and C4161 were identified in 5/36 (14%) of control subjects (7% of chromosomes) and were always observed together. Phenotype-genotype correlation. Phenotype data, collected from a total of 11 affected individuals spanning six generations, are presented in Table I . Striking variability was noted in the age at onset, distribution, and severity of involvement of the ocular, skeletal, and cardiovascular systems despite inheritance ofthe same mutant fibrillin allele. Notable observation include the variability in life-threatening cardiovascular complications, the apparent paucity ofmanifestations in individual III-2 (phenotype deduced from family history, medical records, and death certificate), despite her being an obligate carrier, and the fact that the only two affected individuals with the identical phenotype were monozygotic twins (V-5 and V-6).
Discussion
Commencing in the 1950s, clinical studies of large numbers of patients with the Marfan syndrome and their families delineated the natural history of this disorder, defined the wide range of tissue involvement (pleiotropy) and clinical variability, and established autosomal dominant inheritance with a high incidence ofsporadic cases. These observations led to speculation that a unitary defect of a structural and nonenzymatic component of the extracellular matrix, encoded by a gene susceptible to mutation, and expressed in a diversity oftissues, was the cause of the Marfan syndrome. Recent advances in the understanding of the molecular basis ofthis disease have demonstrated the accuracy of these predictions.
The combined data from linkage analysis, including the apparent lack of genetic heterogeneity in patients with diverse ethnic backgrounds (18) , in situ chromosome localization studies (12, 13), and biochemical inquiry (6, 7) established fibrillin as the leading candidate for the site of defect in the Marfan syndrome. The identification of fibrillin gene mutations in patients with sporadic disease provided definitive evidence for this limited population (1 1). Now, the identification ofa mutation in the fibrillin gene that segregates with disease phenotype in a family substantiates its role in the pathogenesis ofinherited Marfan syndrome. In addition, the ability to follow the segregation pattern of C1409S allows observation and comment regarding penetrance of fibrillin genotype and the origins of pleiotropy and intrafamilial phenotypic variability.
There is a compelling body of evidence to suggest that C 1409S is indeed a disease-producing mutation. First, this alteration was not observed during screening of 176 chromosomes from the normal population. It is therefore unlikely to be a neutral polymorphism. Second, the mutation substitutes one of six cysteines that occur in each of 34 identified EGF-like motifs in the fibrillin gene (10) . This motifhas been recognized in a wide array of human, other vertebrate and invertebrate proteins and the six cysteine residues are invariant (19) . This degree of evolutionary conservation suggests functional significance. The alignment ofa consensus sequence for the EGF-like repeats in human proteins with relevance to the extracellular matrix (10, (20) (21) (22) (23) (24) is shown in Fig. 3 . Third, although the role of the fibrillin-repetitive, EGF-like motif and its cysteine residues is uncertain, much has been learned about the function of homologous sequences from the study of other proteins. The sulfhydryl group of cysteine is unique in its ability to participate in disulfide covalent cross-linkage. In fact, two thirds of fibrillin cysteine residues exist in the half-cystinyl form, suggesting their participation in intramolecular disulfide linkage (25) . In human EGF all six cysteines participate in the formation of intramolecular covalent bonds resulting in an anti-parallel 3-sheet conformation (26 eralizable to fibrillin. The cysteine residues in the EGF-like motif may also be necessary for intermolecular interactions with other fibrillin molecules or with other proteins (25) . Finally, the mutated cysteine in C 1409S occurs within the subsequence C X D/N X X X X F/Y X C X C, which is thought to be a consensus site for ft-hydroxylation ofaspartic acid and asparagine, as observed in the vitamin K-dependent plasma proteins, LDL receptor, and bovine thrombomodulin (27) . The fl-hydroxylated residues are thought to participate in calcium binding, an event that may be necessary to stabilize p3-sheet conformation (26, 27) . Therefore, substitution ofthis vital cysteine residue might be expected to result in an alteration of fibrillin secondary or tertiary structure, impairment of fibrillin interactions with other elements ofthe extracellular matrix, or both, thereby producing a mutant phenotype. A mechanism currently proposed for the dominant inheritance of disease involves interruption of gene function at the protein level when the activity ofthe wild-type gene product is inhibited by a mutant variant of the same product, so-called "protein suicide" (28) . Such "dominant-negative" mutations can exert their inhibition by producing a mutant molecule that participates with the normal product in the formation ofstructurally and hence functionally abnormal multimers, as observed with type I collagen defects in osteogenesis imperfecta (29) . In contrast, the mutant product can interrupt the machinery necessary for normal protein metabolism or interactions with other proteins (such as transport mechanisms or receptors). In this regard, it is interesting to note that normal microfibrillar assembly requires fibrillin molecules to form intermolecular disulfide bond aggregates (25) , and that the fibrillin microfibril has been suggested to associate with many other components of the extracellular matrix (30) (31) (32) (33) . Alternatively, the phenotype may simply be the result of a reduction in wildtype product.
Penetrance of mutation C 1409S appears to be complete in the family presented. There are no individuals who carry this substitution who do not have manifestations of the Marfan syndrome observed in at least one organ system. The degree of variability in age at onset, distribution, and severity of organ system involvement, however, is quite striking. The only family members who were suspect for the diagnosis of the Marfan syndrome before this study were the proband (IV-1) and her daughter (V-3). In fact, according to medical records, it was believed that the proband represented a sporadic occurrence of the disease. Therefore, ifone includes comprehensive genotype and historical phenotype assessment, an additional nine individuals were assigned "affected" status. The decision not to evaluate more fully for the diagnosis, despite the presence of nonspecific skeletal features, had been based upon the lack of apparent and classic involvement of other organ systems, features seen in the proband. Phenotypic variation was central to this decision-making process. The fact that multiple family members died from cardiovascular complications of the Marfan syndrome despite relatively mild involvement of other tissues underscores the utility of presymptomatic diagnosis through linkage or direct mutational analyses and the necessity for careful evaluation and routine follow-up ofall Marfan family members with any suggestion of phenotypic abnormality.
That the Marfan phenotype is not solely determined by mutant fibrillin allele genotype suggests a prominent role for tissue-specific genetic or environmental modifiers. The identical phenotype of the affected monozygotic twins presented in this study, despite wide clinical variability in the extended family, supports speculation that alleles of other genes influence the expression of mutant fibrillin alleles. It is also possible that polymorphic alleles of the fibrillin gene interact with the mutant fibrillin allele to enhance or mask features of the mutant phenotype. These issues can only be resolved with the identification of many more mutations, ongoing phenotype-genotype correlations, and the use of transgenic or other experimental technologies which mimic the complexity of the human system.
